Alimera Sciences Key Executives
This section highlights Alimera Sciences's key executives, including their titles and compensation details.
Find Contacts at Alimera Sciences
(Showing 0 of )
Alimera Sciences Earnings
This section highlights Alimera Sciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2024 | 2024-05-14 | $-0.06 | $-0.12 |
| Read Transcript | Q4 | 2023 | 2024-03-07 | $0.02 | $-0.07 |
| Read Transcript | Q3 | 2023 | 2023-10-26 | $-0.41 | $-0.06 |
| Read Transcript | Q2 | 2023 | 2023-08-10 | $0.06 | $-0.44 |
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
$5.54
Stock Price
$301.29M
Market Cap
159
Employees
Alpharetta, GA
Location
Financial Statements
Access annual & quarterly financial statements for Alimera Sciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $80.75M | $54.13M | $59.03M | $50.82M | $53.94M |
| Cost of Revenue | $19.58M | $7.98M | $7.03M | $6.94M | $6.63M |
| Gross Profit | $61.17M | $46.15M | $52.00M | $43.88M | $47.32M |
| Gross Profit Ratio | 75.70% | 85.26% | 88.10% | 86.34% | 87.72% |
| Research and Development Expenses | $16.63M | $16.23M | $13.78M | $9.67M | $10.99M |
| General and Administrative Expenses | $18.53M | $12.87M | $12.77M | $11.65M | $13.95M |
| Selling and Marketing Expenses | $27.95M | $25.99M | $23.07M | $20.38M | $25.00M |
| Selling General and Administrative Expenses | $46.02M | $38.86M | $35.84M | $32.04M | $38.96M |
| Other Expenses | $- | $2.71M | $2.58M | $2.68M | $2.64M |
| Operating Expenses | $62.64M | $57.79M | $52.20M | $44.38M | $52.59M |
| Cost and Expenses | $82.22M | $65.77M | $59.23M | $51.32M | $59.22M |
| Interest Income | $- | $5.88M | $5.41M | $5.38M | $4.87M |
| Interest Expense | $10.19M | $5.88M | $5.41M | $5.38M | $4.87M |
| Depreciation and Amortization | $8.75M | $2.71M | $2.58M | $2.68M | $2.64M |
| EBITDA | $7.28M | $-8.93M | $2.38M | $2.17M | $-2.63M |
| EBITDA Ratio | 9.01% | -16.51% | 4.03% | 4.28% | -4.88% |
| Operating Income | $-1.47M | $-11.64M | $-201.00K | $-501.00K | $-5.27M |
| Operating Income Ratio | -1.82% | -21.50% | -0.34% | -0.99% | -9.78% |
| Total Other Income Expenses Net | $-18.11M | $-6.44M | $-3.73M | $-4.91M | $-4.95M |
| Income Before Tax | $-20.05M | $-18.08M | $-3.93M | $-5.41M | $-10.23M |
| Income Before Tax Ratio | -24.82% | -33.40% | -6.66% | -10.64% | -18.96% |
| Income Tax Expense | $85.00K | $28.00K | $438.00K | $-68.00K | $216.00K |
| Net Income | $-20.13M | $-18.11M | $-4.37M | $-5.34M | $-10.44M |
| Net Income Ratio | -24.93% | -33.45% | -7.41% | -10.51% | -19.36% |
| EPS | $-0.79 | $-2.59 | $-0.66 | $-1.04 | $-2.19 |
| EPS Diluted | $-0.79 | $-2.59 | $-0.66 | $-1.04 | $-2.19 |
| Weighted Average Shares Outstanding | 25.56M | 7.00M | 6.60M | 5.12M | 4.77M |
| Weighted Average Shares Outstanding Diluted | 25.56M | 7.00M | 6.60M | 5.12M | 4.77M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.00M | $23.01M | $26.31M | $23.36M | $17.54M | $13.55M | $14.03M | $13.60M | $14.60M | $11.90M | $13.96M | $12.15M | $21.70M | $11.21M | $13.77M | $12.47M | $10.04M | $14.54M | $17.35M | $12.85M |
| Cost of Revenue | $6.92M | $6.44M | $6.67M | $2.76M | $2.42M | $2.03M | $2.12M | $2.01M | $2.17M | $1.68M | $1.97M | $1.69M | $1.81M | $1.56M | $1.99M | $1.54M | $1.49M | $1.93M | $2.27M | $1.58M |
| Gross Profit | $20.08M | $16.57M | $19.64M | $20.61M | $15.11M | $11.52M | $11.90M | $11.59M | $12.44M | $10.22M | $11.99M | $10.46M | $19.89M | $9.65M | $11.78M | $10.94M | $8.55M | $12.61M | $15.07M | $11.27M |
| Gross Profit Ratio | 74.40% | 72.00% | 74.70% | 88.20% | 86.20% | 85.00% | 84.90% | 85.20% | 85.20% | 85.90% | 85.90% | 86.10% | 91.60% | 86.10% | 85.54% | 87.68% | 85.21% | 86.74% | 86.90% | 87.71% |
| Research and Development Expenses | $4.26M | $4.36M | $4.77M | $4.04M | $3.65M | $4.16M | $4.23M | $4.48M | $3.93M | $3.58M | $3.72M | $3.28M | $3.57M | $3.21M | $2.51M | $2.47M | $1.81M | $2.88M | $2.67M | $2.76M |
| General and Administrative Expenses | $7.38M | $5.43M | $6.38M | $3.61M | $4.37M | $4.17M | $3.33M | $3.35M | $2.94M | $3.24M | $3.20M | $2.81M | $3.36M | $3.41M | $3.46M | $2.62M | $2.98M | $3.18M | $3.77M | $3.12M |
| Selling and Marketing Expenses | $8.51M | $9.08M | $7.77M | $7.94M | $6.43M | $5.80M | $5.76M | $6.50M | $6.87M | $6.85M | $7.17M | $5.75M | $5.33M | $4.82M | $4.99M | $4.76M | $4.38M | $5.67M | $6.55M | $6.44M |
| Selling General and Administrative Expenses | $15.88M | $14.34M | $13.69M | $11.55M | $10.81M | $9.97M | $9.10M | $9.86M | $9.81M | $10.09M | $10.37M | $8.56M | $8.69M | $8.23M | $8.44M | $7.38M | $7.36M | $8.85M | $10.31M | $9.56M |
| Other Expenses | $- | $- | $-1.08M | $402.00K | $- | $681.00K | $683.00K | $664.00K | $670.00K | $689.00K | $659.00K | $649.00K | $633.00K | $638.00K | $660.00K | $677.00K | $685.00K | $654.00K | $667.00K | $668.00K |
| Operating Expenses | $20.14M | $18.70M | $18.45M | $15.99M | $16.32M | $14.82M | $14.01M | $15.00M | $14.41M | $14.37M | $14.74M | $12.49M | $12.89M | $12.08M | $11.61M | $10.53M | $9.85M | $12.39M | $13.65M | $12.99M |
| Cost and Expenses | $27.06M | $25.14M | $25.12M | $18.75M | $18.75M | $16.85M | $16.14M | $17.01M | $16.58M | $16.05M | $16.71M | $14.18M | $14.70M | $13.64M | $13.60M | $12.07M | $11.34M | $14.32M | $15.92M | $14.57M |
| Interest Income | $- | $- | $- | $2.07M | $1.69M | $1.67M | $1.63M | $1.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $3.15M | $3.74M | $4.75M | $2.07M | $1.69M | $1.67M | $1.63M | $1.50M | $1.38M | $1.36M | $1.36M | $1.36M | $1.35M | $1.34M | $1.45M | $1.28M | $1.35M | $1.29M | $1.17M | $1.23M |
| Depreciation and Amortization | $3.09M | $3.08M | $3.04M | $3.16M | $1.87M | $681.00K | $683.00K | $664.00K | $670.00K | $689.00K | $659.00K | $649.00K | $633.00K | $638.00K | $660.00K | $677.00K | $685.00K | $654.00K | $667.00K | $668.00K |
| EBITDA | $3.03M | $959.00K | $4.02M | $3.93M | $658.00K | $-2.62M | $-1.43M | $-2.75M | $-1.30M | $-3.46M | $-2.09M | $-1.37M | $7.64M | $-1.79M | $833.00K | $1.08M | $-614.00K | $872.00K | $2.15M | $-1.05M |
| EBITDA Ratio | 11.23% | 4.17% | 15.00% | 17.00% | 3.75% | -19.35% | -10.16% | -20.20% | -8.93% | -29.06% | -14.99% | -11.30% | 35.18% | -15.98% | 6.05% | 8.69% | -6.12% | 6.00% | 12.07% | -8.16% |
| Operating Income | $-62.00K | $-2.13M | $1.19M | $1.85M | $-1.21M | $-3.30M | $-2.11M | $-3.41M | $-1.97M | $-4.15M | $-2.75M | $-2.02M | $7.00M | $-2.43M | $173.00K | $407.00K | $-1.30M | $218.00K | $1.43M | $-1.72M |
| Operating Income Ratio | -0.23% | -9.24% | 4.50% | 7.94% | -6.89% | -24.38% | -15.03% | -25.08% | -13.52% | -34.85% | -19.71% | -16.64% | 32.27% | -21.67% | 1.26% | 3.26% | -12.94% | 1.50% | 8.23% | -13.35% |
| Total Other Income Expenses Net | $-3.28M | $-3.98M | $-4.50M | $-3.15M | $-8.80M | $-1.67M | $-1.67M | $-1.83M | $-1.12M | $-1.81M | $-1.39M | $-2.33M | $1.20M | $-1.22M | $-1.27M | $-1.02M | $-1.24M | $-1.37M | $-1.12M | $-1.35M |
| Income Before Tax | $-3.35M | $-6.28M | $-3.77M | $-1.41M | $-10.00M | $-4.97M | $-3.78M | $-5.25M | $-3.10M | $-5.96M | $-4.14M | $-4.35M | $8.21M | $-3.65M | $-1.10M | $-611.00K | $-2.54M | $-1.16M | $305.00K | $-3.06M |
| Income Before Tax Ratio | -12.42% | -27.30% | -14.35% | -6.02% | -57.04% | -36.68% | -26.95% | -38.57% | -21.21% | -50.05% | -29.65% | -35.81% | 37.81% | -32.53% | -7.99% | -4.90% | -25.31% | -7.95% | 1.76% | -23.84% |
| Income Tax Expense | $-43.00K | $-32.00K | $7.00K | $-53.00K | $25.00K | $3.33M | $-1.00K | $12.00K | $17.00K | $1.81M | $-33.00K | $-169.00K | $640.00K | $1.34M | $-123.00K | $7.00K | $5.00K | $43.00K | $-193.00K | $77.00K |
| Net Income | $-3.31M | $-6.25M | $-3.78M | $-1.35M | $-10.03M | $-8.30M | $-3.78M | $-5.26M | $-3.12M | $-7.76M | $-4.11M | $-4.18M | $6.99M | $-3.65M | $-977.00K | $-618.00K | $-2.55M | $-1.20M | $498.00K | $-3.14M |
| Net Income Ratio | -12.26% | -27.17% | -14.37% | -5.80% | -57.18% | -61.28% | -26.94% | -38.66% | -21.33% | -65.25% | -29.41% | -34.42% | 32.20% | -32.53% | -7.09% | -4.95% | -25.36% | -8.24% | 2.87% | -24.44% |
| EPS | $-0.06 | $-0.11 | $-0.07 | $-0.04 | $-1.24 | $-1.18 | $-0.54 | $-0.75 | $-0.45 | $-1.11 | $-0.59 | $-0.60 | $1.03 | $-0.63 | $-0.18 | $-0.12 | $-0.51 | $-0.24 | $0.08 | $-0.66 |
| EPS Diluted | $-0.06 | $-0.11 | $-0.07 | $-0.04 | $-1.24 | $-1.18 | $-0.54 | $-0.75 | $-0.45 | $-1.11 | $-0.59 | $-0.60 | $1.03 | $-0.63 | $-0.18 | $-0.12 | $-0.51 | $-0.24 | $0.08 | $-0.66 |
| Weighted Average Shares Outstanding | 54.38M | 54.36M | 54.42M | 32.11M | 8.09M | 7.03M | 7.00M | 7.00M | 7.00M | 6.99M | 6.92M | 6.92M | 7.35M | 5.76M | 5.39M | 5.07M | 4.99M | 4.98M | 6.18M | 4.73M |
| Weighted Average Shares Outstanding Diluted | 54.38M | 54.36M | 54.42M | 32.11M | 8.09M | 7.03M | 7.00M | 7.00M | 7.00M | 6.99M | 6.93M | 6.92M | 7.36M | 5.76M | 5.39M | 5.07M | 5.03M | 4.98M | 6.20M | 4.73M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $12.09M | $5.27M | $16.51M | $11.21M | $9.43M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $12.09M | $5.27M | $16.51M | $11.21M | $9.43M |
| Net Receivables | $34.55M | $19.61M | $19.13M | $17.20M | $19.33M |
| Inventory | $1.88M | $1.60M | $2.68M | $2.75M | $1.39M |
| Other Current Assets | $3.94M | $2.92M | $3.84M | $3.75M | $2.60M |
| Total Current Assets | $52.42M | $29.41M | $42.16M | $34.91M | $32.74M |
| Property Plant Equipment Net | $3.59M | $3.92M | $4.49M | $2.36M | $2.05M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $97.36M | $8.96M | $10.90M | $12.84M | $14.78M |
| Goodwill and Intangible Assets | $97.36M | $8.96M | $10.90M | $12.84M | $14.78M |
| Long Term Investments | $- | $183.00K | $833.00K | $15.20M | $16.83M |
| Tax Assets | $104.00K | $129.00K | $137.00K | $753.00K | $734.00K |
| Other Non-Current Assets | $52.00K | $- | $- | $-15.20M | $-16.83M |
| Total Non-Current Assets | $101.10M | $13.19M | $16.36M | $15.95M | $17.56M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $153.52M | $42.60M | $58.52M | $50.85M | $50.31M |
| Account Payables | $8.25M | $10.09M | $8.71M | $7.46M | $7.08M |
| Short Term Debt | $828.00K | $26.41M | $489.00K | $2.10M | $724.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $12.83M | $3.23M | $3.40M | $2.79M | $4.25M |
| Total Current Liabilities | $21.91M | $39.73M | $12.59M | $12.35M | $12.05M |
| Long Term Debt | $64.49M | $18.68M | $43.08M | $42.92M | $38.75M |
| Deferred Revenue Non-Current | $- | $- | $- | $1.00M | $1.00M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $-1.00M | $-1.00M |
| Other Non-Current Liabilities | $20.95M | $5.04M | $5.45M | $3.56M | $3.95M |
| Total Non-Current Liabilities | $85.44M | $23.72M | $48.53M | $46.48M | $42.71M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $107.35M | $63.45M | $61.12M | $58.83M | $54.75M |
| Preferred Stock | $3.87M | $19.23M | $19.23M | $19.23M | $30.34M |
| Common Stock | $524.00K | $70.00K | $69.00K | $57.00K | $50.00K |
| Retained Earnings | $-418.49M | $-415.39M | $-397.28M | $-392.91M | $-387.57M |
| Accumulated Other Comprehensive Income Loss | $1.69M | $-3.00M | $-1.85M | $-553.00K | $-1.09M |
| Other Total Stockholders Equity | $466.84M | $378.24M | $377.23M | $366.20M | $353.82M |
| Total Stockholders Equity | $46.17M | $-20.85M | $-2.60M | $-7.98M | $-4.45M |
| Total Equity | $46.17M | $-20.85M | $-2.60M | $-7.98M | $-4.45M |
| Total Liabilities and Stockholders Equity | $153.52M | $42.60M | $58.52M | $50.85M | $50.31M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $153.52M | $42.60M | $58.52M | $50.85M | $50.31M |
| Total Investments | $- | $183.00K | $833.00K | $15.20M | $16.83M |
| Total Debt | $67.40M | $44.33M | $43.57M | $44.61M | $39.01M |
| Net Debt | $55.31M | $39.05M | $27.06M | $33.40M | $29.58M |
Balance Sheet Charts
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $10.86M | $14.35M | $12.09M | $8.29M | $18.77M | $13.09M | $5.27M | $5.51M | $7.86M | $9.95M | $16.51M | $21.52M | $24.78M | $8.27M | $11.21M | $11.25M | $13.50M | $12.24M | $9.43M | $7.90M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $10.86M | $14.35M | $12.09M | $8.29M | $18.77M | $13.09M | $5.27M | $5.51M | $7.86M | $9.95M | $16.51M | $21.52M | $24.78M | $8.27M | $11.21M | $11.25M | $13.50M | $12.24M | $9.43M | $7.90M |
| Net Receivables | $37.08M | $34.22M | $34.55M | $33.94M | $22.59M | $18.43M | $19.61M | $19.14M | $20.32M | $18.78M | $19.13M | $16.21M | $15.09M | $15.70M | $17.20M | $15.63M | $14.03M | $16.18M | $19.33M | $16.38M |
| Inventory | $3.46M | $2.21M | $1.88M | $1.76M | $1.05M | $1.22M | $1.60M | $1.79M | $1.66M | $2.45M | $2.68M | $2.30M | $2.31M | $2.59M | $2.75M | $2.52M | $1.97M | $1.20M | $1.39M | $1.64M |
| Other Current Assets | $4.05M | $3.69M | $3.94M | $4.41M | $3.60M | $2.94M | $2.92M | $3.32M | $3.24M | $3.58M | $3.84M | $3.60M | $3.06M | $3.77M | $3.75M | $3.21M | $2.97M | $2.53M | $2.60M | $2.19M |
| Total Current Assets | $55.41M | $54.47M | $52.42M | $48.40M | $46.02M | $35.67M | $29.41M | $29.76M | $33.07M | $34.75M | $42.16M | $43.63M | $45.24M | $30.33M | $34.91M | $32.61M | $32.47M | $32.15M | $32.74M | $28.11M |
| Property Plant Equipment Net | $3.27M | $3.44M | $3.59M | $3.62M | $3.74M | $3.76M | $3.92M | $3.87M | $3.94M | $4.34M | $4.49M | $3.38M | $2.20M | $2.18M | $2.36M | $2.37M | $2.07M | $1.83M | $2.05M | $2.22M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $91.59M | $94.47M | $97.36M | $101.97M | $104.94M | $8.48M | $8.96M | $9.45M | $9.94M | $10.42M | $10.90M | $11.39M | $11.88M | $12.36M | $12.84M | $13.33M | $13.82M | $14.30M | $14.78M | $15.27M |
| Goodwill and Intangible Assets | $91.59M | $94.47M | $97.36M | $101.97M | $104.94M | $8.48M | $8.96M | $9.45M | $9.94M | $10.42M | $10.90M | $11.39M | $11.88M | $12.36M | $12.84M | $13.33M | $13.82M | $14.30M | $14.78M | $15.27M |
| Long Term Investments | $- | $- | $- | $- | $93.00K | $197.00K | $183.00K | $235.00K | $502.00K | $282.00K | $833.00K | $-11.39M | $-11.88M | $-12.36M | $-753.00K | $-767.00K | $-735.00K | $-720.00K | $-734.00K | $-1.13M |
| Tax Assets | $101.00K | $102.00K | $104.00K | $127.00K | $131.00K | $131.00K | $129.00K | $118.00K | $126.00K | $134.00K | $137.00K | $712.00K | $729.00K | $720.00K | $753.00K | $767.00K | $735.00K | $720.00K | $734.00K | $1.13M |
| Other Non-Current Assets | $7.00K | $6.00K | $52.00K | $70.00K | $- | $- | $- | $- | $- | $- | $- | $12.34M | $13.94M | $12.36M | $753.00K | $767.00K | $735.00K | $720.00K | $734.00K | $1.13M |
| Total Non-Current Assets | $94.97M | $98.02M | $101.10M | $105.79M | $108.90M | $12.56M | $13.19M | $13.67M | $14.50M | $15.18M | $16.36M | $16.43M | $16.86M | $15.26M | $15.95M | $16.47M | $16.62M | $16.85M | $17.56M | $18.62M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $150.38M | $152.49M | $153.52M | $154.19M | $154.92M | $48.24M | $42.60M | $43.43M | $47.57M | $49.93M | $58.52M | $60.06M | $62.10M | $45.59M | $50.85M | $49.08M | $49.09M | $49.00M | $50.31M | $46.73M |
| Account Payables | $10.21M | $10.31M | $8.25M | $6.21M | $8.04M | $9.67M | $10.09M | $8.71M | $7.61M | $6.60M | $8.71M | $7.44M | $7.08M | $6.34M | $7.46M | $5.36M | $5.88M | $5.83M | $7.08M | $6.73M |
| Short Term Debt | $245.00K | $220.00K | $828.00K | $193.00K | $203.00K | $263.00K | $26.41M | $21.64M | $14.50M | $7.36M | $489.00K | $289.00K | $301.00K | $1.99M | $2.10M | $1.40M | $1.11M | $243.00K | $724.00K | $4.04M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $405.00K | $- | $- | $- | $469.00K | $449.00K |
| Other Current Liabilities | $9.38M | $10.26M | $12.83M | $11.32M | $6.00M | $4.24M | $3.23M | $3.66M | $3.32M | $3.05M | $3.40M | $3.67M | $2.92M | $2.87M | $2.79M | $3.48M | $3.14M | $3.04M | $4.25M | $3.47M |
| Total Current Liabilities | $19.84M | $20.79M | $21.91M | $17.72M | $14.24M | $14.17M | $39.73M | $34.01M | $25.43M | $17.01M | $12.59M | $11.40M | $10.31M | $11.21M | $12.35M | $10.23M | $10.14M | $9.12M | $12.05M | $14.23M |
| Long Term Debt | $69.73M | $69.44M | $64.49M | $64.22M | $63.95M | $44.15M | $18.68M | $22.49M | $29.30M | $36.24M | $43.08M | $42.84M | $42.59M | $42.80M | $42.92M | $42.91M | $42.82M | $41.49M | $38.75M | $35.30M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $22.02M | $21.61M | $20.95M | $23.41M | $30.49M | $8.83M | $5.04M | $5.00M | $5.18M | $5.28M | $5.45M | $4.33M | $3.31M | $3.54M | $3.56M | $3.57M | $3.66M | $3.79M | $3.95M | $3.67M |
| Total Non-Current Liabilities | $91.75M | $91.04M | $85.44M | $87.63M | $94.45M | $52.98M | $23.72M | $27.50M | $34.48M | $41.53M | $48.53M | $47.16M | $45.90M | $46.34M | $46.48M | $46.48M | $46.48M | $45.28M | $42.71M | $38.97M |
| Other Liabilities | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $111.59M | $111.83M | $107.35M | $105.35M | $108.69M | $67.16M | $63.45M | $61.51M | $59.91M | $58.53M | $61.12M | $58.56M | $56.21M | $57.55M | $58.83M | $56.71M | $56.62M | $54.40M | $54.75M | $53.20M |
| Preferred Stock | $- | $- | $3.87M | $4.40M | $74.72M | $7.73M | $19.23M | $19.23M | $19.23M | $19.23M | $19.23M | $19.23M | $19.23M | $19.23M | $19.23M | $28.70M | $30.34M | $30.34M | $30.34M | $30.34M |
| Common Stock | $524.00K | $524.00K | $524.00K | $524.00K | $88.00K | $74.00K | $70.00K | $70.00K | $70.00K | $70.00K | $69.00K | $69.00K | $69.00K | $58.00K | $57.00K | $51.00K | $50.00K | $50.00K | $50.00K | $710.00K |
| Retained Earnings | $-428.05M | $-424.74M | $-418.49M | $-414.71M | $-412.78M | $-402.08M | $-415.39M | $-411.61M | $-406.35M | $-403.24M | $-397.28M | $-393.18M | $-388.99M | $-396.56M | $-392.91M | $-391.93M | $-391.31M | $-388.77M | $-387.57M | $-388.07M |
| Accumulated Other Comprehensive Income Loss | $1.49M | $1.54M | $1.69M | $-2.99M | $-2.78M | $-2.78M | $-3.00M | $-3.77M | $-3.13M | $-2.21M | $-1.85M | $-1.57M | $-1.12M | $-1.15M | $-553.00K | $-888.00K | $-1.09M | $-1.18M | $-1.09M | $-1.20M |
| Other Total Stockholders Equity | $464.82M | $467.72M | $466.84M | $466.02M | $386.98M | $378.15M | $378.24M | $378.00M | $377.85M | $377.54M | $377.23M | $376.95M | $376.70M | $366.46M | $366.20M | $356.44M | $354.48M | $354.15M | $353.82M | $351.74M |
| Total Stockholders Equity | $38.79M | $40.65M | $46.17M | $48.84M | $46.23M | $-18.92M | $-20.85M | $-18.08M | $-12.34M | $-8.60M | $-2.60M | $1.50M | $5.89M | $-11.96M | $-7.98M | $-7.63M | $-7.53M | $-5.40M | $-4.45M | $-6.48M |
| Total Equity | $38.79M | $40.65M | $46.17M | $48.84M | $46.23M | $-18.92M | $-20.85M | $-18.08M | $-12.34M | $-8.60M | $-2.60M | $1.50M | $5.89M | $-11.96M | $-7.98M | $-7.63M | $-7.53M | $-5.40M | $-4.45M | $-6.48M |
| Total Liabilities and Stockholders Equity | $150.38M | $152.49M | $153.52M | $154.19M | $154.92M | $48.24M | $42.60M | $43.43M | $47.57M | $49.93M | $58.52M | $60.06M | $62.10M | $45.59M | $50.85M | $49.08M | $49.09M | $49.00M | $50.31M | $46.73M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $150.38M | $152.49M | $153.52M | $154.19M | $154.92M | $48.24M | $42.60M | $43.43M | $47.57M | $49.93M | $58.52M | $60.06M | $62.10M | $45.59M | $50.85M | $49.08M | $49.09M | $49.00M | $50.31M | $46.73M |
| Total Investments | $- | $- | $- | $- | $93.00K | $197.00K | $183.00K | $235.00K | $502.00K | $282.00K | $833.00K | $-11.39M | $-11.88M | $-12.36M | $-753.00K | $-767.00K | $-735.00K | $-720.00K | $-734.00K | $-1.13M |
| Total Debt | $72.16M | $72.25M | $67.40M | $64.42M | $64.16M | $44.41M | $44.33M | $44.13M | $43.80M | $43.60M | $43.57M | $43.13M | $42.90M | $44.80M | $44.61M | $44.31M | $43.94M | $41.73M | $39.01M | $38.89M |
| Net Debt | $61.30M | $57.91M | $55.31M | $56.13M | $45.38M | $31.33M | $39.05M | $38.62M | $35.94M | $33.66M | $27.06M | $21.60M | $18.12M | $36.53M | $33.40M | $33.06M | $30.44M | $29.49M | $29.58M | $30.99M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-20.13M | $-18.11M | $-4.37M | $-5.34M | $-10.44M |
| Depreciation and Amortization | $8.75M | $2.71M | $2.58M | $2.68M | $2.64M |
| Deferred Income Tax | $29.00K | $116.00K | $610.00K | $31.00K | $454.00K |
| Stock Based Compensation | $1.44M | $910.00K | $997.00K | $1.33M | $2.46M |
| Change in Working Capital | $-15.80M | $2.69M | $-1.35M | $-1.39M | $-181.00K |
| Accounts Receivables | $-17.16M | $-863.00K | $-2.21M | $2.63M | $-2.16M |
| Inventory | $-260.00K | $1.01M | $-19.00K | $-1.26M | $996.00K |
| Accounts Payables | $-1.88M | $1.47M | $1.49M | $106.00K | $779.00K |
| Other Working Capital | $3.49M | $1.07M | $-609.00K | $-2.87M | $204.00K |
| Other Non Cash Items | $11.46M | $1.71M | $-1.69M | $498.00K | $921.00K |
| Net Cash Provided by Operating Activities | $-14.26M | $-9.97M | $-3.22M | $-2.19M | $-4.15M |
| Investments in Property Plant and Equipment | $-75.53M | $-255.00K | $-621.00K | $-620.00K | $-174.00K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-75.27M | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-75.53M | $-255.00K | $-621.00K | $-620.00K | $-174.00K |
| Debt Repayment | $22.02M | $-289.00K | $-221.00K | $3.85M | $-33.00K |
| Common Stock Issued | $2.40M | $85.00K | $10.08M | $49.00K | $902.00K |
| Common Stock Repurchased | $-314.00K | $- | $- | $- | $- |
| Dividends Paid | $-1.26M | $- | $- | $- | $- |
| Other Financing Activities | $73.65M | $-98.00K | $-40.00K | $-19.00K | $- |
| Net Cash Used Provided by Financing Activities | $96.50M | $-302.00K | $9.82M | $3.88M | $869.00K |
| Effect of Forex Changes on Cash | $80.00K | $-708.00K | $-676.00K | $714.00K | $-159.00K |
| Net Change in Cash | $6.79M | $-11.24M | $5.30M | $1.78M | $-3.62M |
| Cash at End of Period | $12.09M | $5.30M | $16.54M | $11.24M | $9.46M |
| Cash at Beginning of Period | $5.30M | $16.54M | $11.24M | $9.46M | $13.07M |
| Operating Cash Flow | $-14.26M | $-9.97M | $-3.22M | $-2.19M | $-4.15M |
| Capital Expenditure | $-75.53M | $-255.00K | $-621.00K | $-620.00K | $-174.00K |
| Free Cash Flow | $-89.79M | $-10.23M | $-3.85M | $-2.81M | $-4.33M |
Cash Flow Charts
| Breakdown | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-3.31M | $-6.25M | $-3.78M | $-1.35M | $-10.03M | $-4.97M | $-3.78M | $-5.26M | $-3.12M | $-5.96M | $-4.11M | $-4.18M | $7.57M | $-3.65M | $-977.00K | $-618.00K | $-2.55M | $-1.20M | $498.00K | $-3.14M |
| Depreciation and Amortization | $3.09M | $3.08M | $3.04M | $3.16M | $1.87M | $681.00K | $683.00K | $664.00K | $670.00K | $689.00K | $659.00K | $649.00K | $633.00K | $638.00K | $660.00K | $677.00K | $685.00K | $654.00K | $667.00K | $668.00K |
| Deferred Income Tax | $43.00K | $- | $29.00K | $1.08M | $7.10M | $- | $116.00K | $169.00K | $- | $- | $610.00K | $169.00K | $-2.55M | $-125.00K | $31.00K | $-267.00K | $-109.00K | $81.00K | $454.00K | $115.00K |
| Stock Based Compensation | $1.46M | $845.00K | $805.00K | $188.00K | $216.00K | $226.00K | $187.00K | $142.00K | $269.00K | $312.00K | $239.00K | $244.00K | $252.00K | $262.00K | $257.00K | $317.00K | $317.00K | $440.00K | $553.00K | $504.00K |
| Change in Working Capital | $-633.00K | $1.09M | $1.16M | $-13.17M | $-5.36M | $1.57M | $2.20M | $1.90M | $556.00K | $-1.97M | $-2.35M | $-654.00K | $1.52M | $132.00K | $-300.00K | $-2.50M | $1.08M | $332.00K | $-1.91M | $-2.26M |
| Accounts Receivables | $-2.94M | $-89.00K | $-2.72M | $-11.58M | $-4.16M | $1.30M | $100.00K | $762.00K | $-1.91M | $184.00K | $-2.97M | $-1.26M | $684.00K | $1.33M | $-1.31M | $-1.36M | $2.27M | $3.04M | $-2.82M | $-2.67M |
| Inventory | $-1.25M | $-333.00K | $-110.00K | $-709.00K | $162.00K | $397.00K | $271.00K | $-203.00K | $739.00K | $203.00K | $-414.00K | $-13.00K | $302.00K | $106.00K | $-155.00K | $-522.00K | $-759.00K | $177.00K | $270.00K | $470.00K |
| Accounts Payables | $2.34M | $2.11M | $1.99M | $-1.80M | $-1.63M | $-434.00K | $1.04M | $1.31M | $1.11M | $-1.99M | $1.32M | $412.00K | $751.00K | $-1.00M | $2.01M | $-695.00K | $-57.00K | $-1.15M | $282.00K | $-1.03M |
| Other Working Capital | $1.22M | $-595.00K | $1.99M | $921.00K | $273.00K | $-1.26M | $793.00K | $36.00K | $614.00K | $-369.00K | $-295.00K | $205.00K | $-213.00K | $-306.00K | $-846.00K | $77.00K | $-372.00K | $-1.73M | $361.00K | $978.00K |
| Other Non Cash Items | $9.92M | $5.99M | $2.52M | $267.00K | $206.00K | $281.00K | $339.00K | $466.00K | $22.00K | $715.00K | $266.00K | $1.04M | $-733.00K | $240.00K | $66.00K | $246.00K | $242.00K | $239.00K | $160.00K | $211.00K |
| Net Cash Provided by Operating Activities | $1.03M | $-566.00K | $3.77M | $-9.83M | $-6.00M | $-2.21M | $-251.00K | $-1.91M | $-1.60M | $-6.21M | $-4.68M | $-2.73M | $6.69M | $-2.50M | $-263.00K | $-2.15M | $-330.00K | $548.00K | $422.00K | $-3.90M |
| Investments in Property Plant and Equipment | $-111.00K | $-21.00K | $-85.00K | $-4.00K | $-75.43M | $-9.00K | $-84.00K | $-130.00K | $108.00K | $-149.00K | $-121.00K | $-310.00K | $-106.00K | $-84.00K | $-85.00K | $-318.00K | $-192.00K | $-25.00K | $-24.00K | $-111.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $-75.27M | $- | $-75.27M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-111.00K | $-21.00K | $-85.00K | $-4.00K | $-75.43M | $-9.00K | $-84.00K | $-130.00K | $108.00K | $-149.00K | $-121.00K | $-310.00K | $-106.00K | $-84.00K | $-85.00K | $-318.00K | $-192.00K | $-25.00K | $-24.00K | $-111.00K |
| Debt Repayment | $-55.00K | $4.87M | $-98.00K | $-136.00K | $19.88M | $2.37M | $-125.00K | $40.00K | $-142.00K | $-62.00K | $-61.00K | $-48.00K | $-55.00K | $-57.00K | $-104.00K | $-110.00K | $1.63M | $2.42M | $2.43M | $-66.00K |
| Common Stock Issued | $- | $37.00K | $20.00K | $-410.00K | $- | $- | $45.00K | $15.00K | $- | $- | $42.00K | $-1.00K | $10.00M | $- | $39.00K | $-10.00K | $- | $- | $868.00K | $8.00K |
| Common Stock Repurchased | $- | $- | $938.00K | $- | $- | $-314.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $-1.26M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-4.30M | $-1.90M | $20.00K | $-410.00K | $64.84M | $7.94M | $-113.00K | $15.00K | $- | $- | $- | $-1.00K | $10.00M | $- | $19.00K | $10.00K | $-6.00K | $-3.00K | $-2.23M | $- |
| Net Cash Used Provided by Financing Activities | $-4.32M | $2.97M | $-78.00K | $-546.00K | $87.12M | $10.00M | $-193.00K | $55.00K | $-102.00K | $-62.00K | $-19.00K | $-49.00K | $9.95M | $-57.00K | $-46.00K | $-110.00K | $1.62M | $2.42M | $1.07M | $-58.00K |
| Effect of Forex Changes on Cash | $-85.00K | $-124.00K | $167.00K | $-115.00K | $-5.00K | $33.00K | $290.00K | $-360.00K | $-497.00K | $-141.00K | $-191.00K | $-166.00K | $-20.00K | $-299.00K | $350.00K | $335.00K | $153.00K | $-124.00K | $58.00K | $-188.00K |
| Net Change in Cash | $-3.48M | $2.26M | $3.77M | $-10.49M | $5.69M | $7.81M | $-238.00K | $-2.35M | $-2.09M | $-6.57M | $-5.01M | $-3.26M | $16.51M | $-2.94M | $-44.00K | $-2.24M | $1.25M | $2.81M | $1.52M | $-4.25M |
| Cash at End of Period | $10.86M | $14.35M | $12.09M | $8.32M | $18.81M | $13.12M | $5.30M | $5.54M | $7.89M | $9.98M | $16.54M | $21.56M | $24.82M | $8.30M | $11.24M | $11.29M | $13.53M | $12.27M | $9.46M | $7.93M |
| Cash at Beginning of Period | $14.35M | $12.09M | $8.32M | $18.81M | $13.12M | $5.30M | $5.54M | $7.89M | $9.98M | $16.54M | $21.56M | $24.82M | $8.30M | $11.24M | $11.29M | $13.53M | $12.27M | $9.46M | $7.93M | $12.19M |
| Operating Cash Flow | $1.03M | $-566.00K | $3.77M | $-9.83M | $-6.00M | $-2.21M | $-251.00K | $-1.91M | $-1.60M | $-6.21M | $-4.68M | $-2.73M | $6.69M | $-2.50M | $-263.00K | $-2.15M | $-330.00K | $548.00K | $422.00K | $-3.90M |
| Capital Expenditure | $-111.00K | $-21.00K | $-85.00K | $-4.00K | $-75.43M | $-9.00K | $-84.00K | $-130.00K | $108.00K | $-149.00K | $-121.00K | $-310.00K | $-106.00K | $-84.00K | $-85.00K | $-318.00K | $-192.00K | $-25.00K | $-24.00K | $-111.00K |
| Free Cash Flow | $915.00K | $-587.00K | $3.69M | $-9.83M | $-81.43M | $-2.22M | $-335.00K | $-2.04M | $-1.49M | $-6.36M | $-4.80M | $-3.04M | $6.59M | $-2.58M | $-348.00K | $-2.47M | $-522.00K | $523.00K | $398.00K | $-4.01M |
Alimera Sciences Dividends
Explore Alimera Sciences's dividend history, including dividend yield, payout ratio, and historical payments.
Alimera Sciences News
Read the latest news about Alimera Sciences, including recent articles, headlines, and updates.
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”).
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM).
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. (“Alimera”) (Nasdaq: ALIM).
Alimera Sciences Reports Second Quarter 2024 Results
ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. (“ANI”).
ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.
New York, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc . ( N asdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in cash at closing and one non-tradable contingent value right ("CVR") to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals. Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent value right (CVR) of $0.50 per share upon the achievement of certain net revenue milestones.
Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing.
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alimera Sciences, Inc. (NASDAQ: ALIM) to ANI Pharmaceuticals, Inc. for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027 is fair to Alimera shareholders. Halper Sadeh encourages Alimera shareholders to click here to learn more about t.
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) approved, on May 22, 2024 (the “Grant Date”), inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan to persons who were not previously employees or who rejoined the Company following a bona fide period of non-employment, as an inducement material to each such new or re-hired employee's employment (collectively, the “Inducement Awards”).
Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President U.S. Operations Philip Ashman - President, International Operations Conference Call Participants Chase Knickerbocker - Craig-Hallum Yi Chen - H.C. Wainwright & Company Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
Alimera Sciences Reports First Quarter 2024 Results
ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q4 2023 Earnings Conference Call March 7, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President & Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President, U.S. Operations Conference Call Participants Alex Nowak - Craig-Hallum Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth Quarter and Fiscal Year 2023 Financial Results and Corporate Update Conference Call.
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME) NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME)
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately.
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ALIM.